- Home
- OGEN vs VWAVW Comparison
OGEN vs VWAVW Comparison
Compare OGEN & VWAVW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGEN
- VWAVW
- Stock Information
- Founded
- OGEN 1996
- VWAVW 2024
- Country
- OGEN United States
- VWAVW United States
- Employees
- OGEN N/A
- VWAVW N/A
- Industry
- OGEN Biotechnology: Pharmaceutical Preparations
- VWAVW Computer Software: Prepackaged Software
- Sector
- OGEN Health Care
- VWAVW Technology
- Exchange
- OGEN Nasdaq
- VWAVW Nasdaq
- Market Cap
- OGEN 1.2M
- VWAVW 1.0M
- IPO Year
- OGEN N/A
- VWAVW N/A
- Fundamental
- Price
- OGEN $1.25
- VWAVW $0.19
- Analyst Decision
- OGEN
- VWAVW
- Analyst Count
- OGEN 0
- VWAVW 0
- Target Price
- OGEN N/A
- VWAVW N/A
- AVG Volume (30 Days)
- OGEN 329.1K
- VWAVW 573.0K
- Earning Date
- OGEN 08-08-2025
- VWAVW 08-27-2025
- Dividend Yield
- OGEN N/A
- VWAVW N/A
- EPS Growth
- OGEN N/A
- VWAVW N/A
- EPS
- OGEN N/A
- VWAVW N/A
- Revenue
- OGEN N/A
- VWAVW N/A
- Revenue This Year
- OGEN N/A
- VWAVW N/A
- Revenue Next Year
- OGEN N/A
- VWAVW N/A
- P/E Ratio
- OGEN N/A
- VWAVW N/A
- Revenue Growth
- OGEN N/A
- VWAVW N/A
- 52 Week Low
- OGEN $1.23
- VWAVW $0.06
- 52 Week High
- OGEN $75.60
- VWAVW $0.48
- Technical
- Relative Strength Index (RSI)
- OGEN 27.96
- VWAVW N/A
- Support Level
- OGEN $1.35
- VWAVW N/A
- Resistance Level
- OGEN $1.49
- VWAVW N/A
- Average True Range (ATR)
- OGEN 0.09
- VWAVW 0.00
- MACD
- OGEN 0.10
- VWAVW 0.00
- Stochastic Oscillator
- OGEN 7.69
- VWAVW 0.00
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.